Richard Chaisson

Medicine & Life Sciences

1. Tuberculosis 100%
2. HIV 90%
3. Isoniazid 38%
4. rifapentine 27%
5. South Africa 22%
6. Acquired Immunodeficiency Syndrome 22%
7. CD4 Lymphocyte Count 22%
8. Therapeutics 19%
9. HIV Infections 19%
10. Virus Diseases 18%
11. HIV-1 16%
12. Highly Active Antiretroviral Therapy 14%
13. Latent Tuberculosis 14%
14. Pulmonary Tuberculosis 14%
15. Brazil 13%
16. Rifampin 12%
17. Tuberculin Test 12%
18. Moxifloxacin 11%
19. Pharmaceutical Preparations 10%
20. Skin Tests 10%
21. Incidence 10%
22. Mycobacterium avium Complex 9%
23. Pyrazinamide 9%
24. Infections 9%
25. Survival 9%
26. efavirenz 8%
27. Drug Users 8%
28. Confidence Intervals 6%
29. Cost-Benefit Analysis 6%
30. Mortality 6%
31. Rifabutin 6%
32. Opportunistic Infections 5%
33. Population 5%
34. Ethambutol 5%
35. Sputum 5%
36. Multidrug-Resistant Tuberculosis 5%
37. Miners 5%
38. Baltimore 5%
39. RNA 5%
40. San Francisco 5%